[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335049-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335049-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mitochondrial-dna-boosted-dendritic-cell-based-nanovaccination-triggers-antitumor-immunity-in-lung-and-pancreatic-cancers","Mitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers","","Low migratory dendritic cell (DC) levels hinder immune surveillance, and their relationship to tumor immune status and immunotherapy outcomes is not well defined. Clinical evidence links reduced migratory DCs with immune-cold tumor phenotypes and poor prognosis. An autologous DC-based nanovaccination is developed using patient-derived organoids or cancer cell lysate-pulsed cationic nanoparticles carrying immunogenic DC-derived microvesicles (cNPcancer cell@MVDC). The strategy increases migratory DCs, activates T and natural killer cells, reduces tumor growth, and improves survival in orthotopic lung and pancreatic cancer models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mitochondrial-dna-boosted-dendritic-cell-based-nanovaccination-triggers-antitumor-immunity-in-lung-and-pancreatic-cancers/335049/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mitochondrial-dna-boosted-dendritic-cell-based-nanovaccination-triggers-antitumor-immunity-in-lung-and-pancreatic-cancers/335049.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address regarding migratory dendritic cells in cancer?","Question",{"text":63,"@type":64},"Low migratory DC levels challenge cancer immune surveillance, but their impact on tumor immune status and immunotherapy response was unclear.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the proposed nanovaccination strategy work?",{"text":68,"@type":64},"It uses autologous DC-based nanovaccination with cationic nanoparticles loaded with immunogenic DC-derived microvesicles (cNPcancer cell@MVDC) prepared from patient-derived organoids or cancer cell lysate.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism is proposed for enhanced dendritic cell activation and migration?",{"text":72,"@type":64},"The approach enriches mitochondrial DNA, which boosts cGAS-STING-mediated DC activation and migration.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335049,1790165403,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":113,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Article  \nMitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers  \nAuthors  \nLihuan Shang, Xue Jiang, Xinbao Zhao, ..., Mingkang Yao, Shanping Jiang,  \nPing-Pui Wong  \nCorrespondence  \n[huangbp3@mail.sysu.edu.cn](huangbp3@mail.sysu.edu.cn)  \nIn brief  \nShang et al. introduce an autologous dendritic cell-based nanovaccination method that supports migratory dendritic cells, potentially transforming immunecold tumors to elicit antitumor immune responses. This approach boosts dendritic cell activity, enhances cytotoxic T lymphocyte activation, and reduces tumor growth, prompting a reevaluation of personalized cancer treatments.  \nd Migratory DC levels correlate with tumor immune status and patient prognosis  \nd We create a nanovaccine, cNPcancer cell@MVDC, to target intratumor DC scarcity  \nd cNPcancer cell@MVDC enhances antitumor immunity beyond conventional DC vaccination  \nd The mtDNA-enriched nanovaccine enhances DC activation through increased cGAS binding  \nShang et al., 2024, Cell Reports Medicine 5, 101648  \nJuly 16, 2024 ª 2024 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2024.101648](https://doi.org/10.1016/j.xcrm.2024.101648)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nMitochondrial DNA-boosted dendritic  \ncell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers  \nLihuan Shang,1,2,5 Xue Jiang,1,2,5 Xinbao Zhao,1,3,5 Xi Huang,1,2 Xiaojuan Wang,1,2 Xue Jiang,1,2 Xiangzhan Kong,1,2 Mingkang Yao,1,2,4 Shanping Jiang,1,2,4 and Ping-Pui Wong1,2,6,*  \n1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, State Key Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou 510120, China  \n2Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China  \n3Department of Ultrasound, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China  \n4Department of Respiratory Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China  \n5These authors contributed equally  \n6Lead contact  \n*Correspondence: [huangbp3@mail.sysu.edu.cn](huangbp3@mail.sysu.edu.cn)  \n[https://doi.org/10.1016/j.xcrm.2024.101648](https://doi.org/10.1016/j.xcrm.2024.101648)  \nSUMMARY  \nLow migratory dendritic cell (DC) levels pose a challenge in cancer immune surveillance, yet their impact on tumor immune status and immunotherapy responses remains unclear. We present clinical evidence linking reduced migratory DC levels to immune-cold tumor status, resulting in poor patient outcomes. To address this, we develop an autologous DC-based nanovaccination strategy using patient-derived organoid or cancer cell lysate-pulsed cationic nanoparticles (cNPs) to load immunogenic DC-derived microvesicles (cNPcancer cell@MVDC) . This approach transforms immune-cold tumors, increases migratory DCs, activates T cells and natural killer cells, reduces tumor growth, and enhances survival in orthotopic pancreatic and lung cancer models, surpassing conventional methods. In vivo imaging reveals superior cNPcancer cell@MVDC accumulation in tumors and lymph nodes, promoting immune cell inﬁltration. Mechanistically, cNPs enrich mitochondrial DNA, enhancing cGAS-STING-mediated DC activation and migration. Our strategy shifts cold tumors to a hot state, enhancing antitumor immunity for potential personalized cancer treatments.  \nINTRODUCTION  \nPancreatic ductal adenocarcinoma (PDAC) poses challenges for therapy due to its unique tumor microenvironment,1 ,2 characterized by limited immune cell inﬁltration and a dense ﬁbrotic matrix.3 Despite attempts with various immunotherapies, such as immune checkpoint inhibitors and dendritic cell (DC) vaccination,4 ,5 PDAC has shown limited responsiveness.6 Unlike PDAC, non-small cell lung cancer (NSCLC) shows pro","cbCaisRDWRdLzVav","https://ap.wps.com/l/cbCaisRDWRdLzVav","pdf",10119225,"English","# SUMMARY\n## Clinical link between migratory DCs and immune-cold tumors\n## Nanovaccine design and antitumor outcomes\n## Mechanism: mtDNA enrichment and cGAS-STING activation\n# INTRODUCTION\n## PDAC tumor microenvironment and immunotherapy limitations\n## NSCLC challenges despite checkpoint therapy\n## Need for improved strategies to convert \"cold\" to \"hot\" tumors\n## Role of CD11c+ migratory DCs and limiting DC scarcity\n## Autologous DC approaches and delivery/activation challenges\n## Microvesicle and DNA-sensing pathways in DC activation","[{\"question\":\"What problem does the study address regarding migratory dendritic cells in cancer?\",\"answer\":\"Low migratory DC levels challenge cancer immune surveillance, but their impact on tumor immune status and immunotherapy response was unclear.\"},{\"question\":\"How does the proposed nanovaccination strategy work?\",\"answer\":\"It uses autologous DC-based nanovaccination with cationic nanoparticles loaded with immunogenic DC-derived microvesicles (cNPcancer cell@MVDC) prepared from patient-derived organoids or cancer cell lysate.\"},{\"question\":\"What mechanism is proposed for enhanced dendritic cell activation and migration?\",\"answer\":\"The approach enriches mitochondrial DNA, which boosts cGAS-STING-mediated DC activation and migration.\"}]","Mitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers | PDF",1790009483,76]